| CURRENT GOOD MANUFACTURING
PRACTICES
NOTIFIED ON MAY 15, 1998 UNDER DRUGS ACT 1976 AND
DRUGS (LICENSING, REGISTERING AND ADVERTISING) RULES 1976.
PUBLISHED BY:
MINISTRY OF HEALTH,
GOVERNMENT OF PAKISTAN
ISLAMABAD
No.F.9-19/96-Lic.
Government of Pakistan
Ministry of Health
*****
Islamabad, the 15th May 1998
S.R.O. 470(I)/98, - In exercise of the powers conferred by section
43 of the Drugs Act, 1976(XXXI of 1976), the Federal Government
of Pakistan to direct that the following further amendments shall
be made in the Drugs (Licensing, shall be made in the Drugs (Licensing
, Registering and Advertising) Rules , 1976, the same having been
previously published as required by sub-section (3) of the said
section, namely :-
In the aforesaid Rules-
I. For rule 2 the following shall be substituted, namely :-
2. Definitions In these rules, unless there is anything repugnant
in the subject or context:-
(a) “active pharmaceutical ingredient” means a substance
pharmacologically active compound (ingredient);
(b) “airlock” means an enclose space with two or more
doors, which is interposed between two or more rooms of differing
classes of cleanliness for the purpose of controlling the airflow
between those rooms when they need to be entered and an airlock
is designed for and used by either people or goods;
(c) “authorized person responsible for the release of batches
of product for sale:
(d) “basic manufacture” means manufacturer of a drug
from basic raw material to a product which is ready for use as a
staring material for the formulation of a finished drug or for repacking
and such manufacture may involve chemical , bio-chemical, photochemical,
microbial or such other processes or a combination of any of such
processes;
(e) “batch (or lot)” means a defined quantity of starting
material, packaging material, or finished product processed in a
single process or series of processes so that it could be expected
to be homogeneous, in the case of continuous manufacture the batch
must correspond to complete to be homogeneous, in the case of continuous
manufacture the batch must correspond to a defined fraction of the
production , characterized by its intended homogeneity, and to complete
certain stages of manufacture it may sometimes be necessary to divide
a batch into a number of sub-batches, which are later brought to
form a final homogeneous batch;
(f) “batch number (or lot number)” means a distinctive
combination of numbers and or letters which specifically identifies
a batch on the labels , the batch to be trace and revived.
(g) “batch numbering system” means a standard operating
procedure describing the details of the batch numbering;
(h) “batch records” means all documents associated with
the manufacture of a batch of bulk product or finished product showing
a history of each batch of product and of all circumstances pertinent
to the quality of the final product;
(i) “biological agents” means micro-organisms, including
genetically engineered microorganisms, cell cultured and endoparasites,
whether pathogenic or not ;
(j) “biological agents” means micro-organisms, including
genetically engineered micro organisms, cell culture and end parasites,
including final packing;
(k) “calibration” means the set of operations that established,
under specified conditions, the relationship between values indicated
by an instruments or meaning system for especially weighing, recording,
and controlling, or the values relationship between values indicated
by an instrument or measuring system for especially weighing, recording,
and controlling, or the values represented by a material measure,
and the corresponding known values of a reference standard and the
limits for acceptance of the results;
(l) “Clean area” means an area with defined environments
control of particulate and microbial contamination, constructed
and used in such a way as to reduce and or eliminate introduction,
generation, and retention of contaminants within the area ;
(m) “compounding” means scientific combination of two
or more ingredients with a view to make a finished;
(n) “consignment or delivery” means the quantity of
starting material, or of a drug product, made by one manufacturer
and supplied at one time in response to a particular request or
order, a consignment may comprise one or more packages or containers
and may include material belonging to more than one batch;
(o) “critical process” means a process that may cause
variation in the quality of the pharmaceutical product;
(p) “cross-contamination” means of a starting material,
intermediate product, or finished product with another starting
martial or drug during production;
(q) “finished product” means a product that has undergone
al stags of production, including packaging in its final container
and labeling;
(r) “Form” means a form set forth in Schedule A;
(s) “formulation” means all operations involved in converting
a drug into a final pharmaceutical dosage form ready for use as
a finished drug including compounding, processing, formulating,
filling, packing, finishing, labeling, and other like processes;
(t) “good manufacturing practices for pharmaceutical products”
means part of quality assurance which:-
(u) “half-finished product” means any material or mixture
of materials that has to undergo further manufacture;
(v) “in-process control” means checks performed during
production in order to monitor and if necessary to adjust the process
to ensure that the product conforms to its specifications and control
of the environment or equipment may also be regarded as a part of
in-process control;
(w) “intermediate product” means partly processed material
that must undergo further manufacturing steps before it becomes
a bulk product;
(x) “large-volume parenteral” means sterile solutions
intended for parenteral application with a volume of more than 100
ml one container of the finished dosage form;
(y) “manufacturer” means all operations of production
, quality control, release, storage and the related controls;
(z) “manufacturer” means a company that carries out
at least one step of manufacturer;
(aa) “manufacturer authorization” means a document,
issued by the Drug Registration Board set up under the Drugs Act,
1976, as a certificate of drug registration;
(ab)“master formula” means a document or set of documents
specifying the starting materials with their quantities and the
packaging materials , together with a description of the procedures
and precautions required to produce a specified quantity of a finished
product as well as the processing instructions, including the in-process
controls;
(ac) “master record” means a documents or set of documents
that as a basis for the batch documentation (blank batch record);
(ad) “new drug” means drug that has not been commonly
sold or distributed to the public in Pakistan and is introduced
for the first time;
(ae) “Ordinance” means the Drug s Ordinance, 1976(IV
of 1976)
(af) “Packing” means all operations, including filling
and labeling which a bulk drug has to undergo in order to become
a finished product;
Note : Sterile filling would not normally be regarded as part of
packaging, the bulk product being the filled , but not the finally
packaged, primary container.
(ag) “Packing material” means any a material, including
printed material, employed in the packing of a pharmaceutical product,
excluding any outer packaging used for transportation or shipment
and packaging material are referred to as primary or secondary according
to whether or not they are intended to be in direct contact with
the product;
(ah) “Pharmaceutical product” means any drug intended
for human use or veterinary use presented in its finished dosage
form or as a starting material for use in such a dosage form;
(ai) “Processing instruction or procedures” means as
defined include (ab) of this section;
(aj) “production” means all operations involved in the
preparation of a pharmaceutical product;
(ak) “Purity” means the degree to which other chemical
or biological entities are present in any substance;
(al) “quality assurance” means the totality of the arrangements
made with the object of ensuring that pharmaceutical products are
of the quality required for their intended use and so incorporates
good manufacturing practices , Quality Control and other factors
including design and development and good laboratory practices;
(am) “quality control” means the part of good manufacturing
practices concerted with sampling, specifications, and necessary
and relevant tests are actually carried out and that materials are
not released for use, nor finished products released procedures
which ensure that the necessary and relevant tests are actually
carried out and that materials are not released for use , nor finished
products released for sale or supply until their quality has been
judged to be satisfactory and it is involved in all decision concerning
the quality of the product;
(an) “quarantine” means status of starting or packing
materials, intermediates, or bulk or finished products isolated
physically or by other effective means while a decisions concerning
the quality of the product;
(ao) “ reconciliation” means a comparison, making due
allowance for normal variation between the amount of product or
used and the amount actually produced or used and the amount actually
produced or used;
(ap) “recovering or blending” means the introduction
of all or part of previous batches or of redistilled solvents and
similar prints of the requires quality into and the batch at defined
stage of manufacture;
(aq) “repacking “ means all operations involved in the
transfer of a drug from a larger container or packing into smaller
xontanes or pickings including filling, packing and labeling with
a view to make it ready for retail sale or wholesale, but does not
includes any compounding , or processing with a view to formulate
it in any dosage form;
“Retail Sale” means a sale other than wholesale.
(as)”reprocessing” means the reworking of all or part
of a barh of product of an unacceptable quality from a refined sage
of production so that its quality may be rendered acceptable by
one or more additional operators;
(at)“returned product” means finished product sent back
to the manufacturer or distributor.
(au) “schedule” means schedule to these rules:
(av) “semi-basic manufacture means manufacture from an intermediate
substance of a drug to be used as starting material for the formulation
of a finished drug or to be used for repacking;
(aw) “specification” means the requirements with which
the products or materials udder or obtained during manufacture must
confirm as specified in the Drugs (Specification) Rules, 1978;
(ax) “standard operating procedure” means an authorized
written procedure including instructions for performing operations
not necessarily specific to a given product or material but of amore
general nature such as control sampling and inspection, and certain
standard operating procedures may be used to supplement specific
master batch production documentation;
(ay) “Starting material” means any substance used in
the production of pharmaceutical product but excluding packing materials;
(az) “system” means a regulated pattern of interacting
activities and techniques which are united to form an organized
whole;
(ba) “validation” means the documents fact of proving
that any procedure process, equipment, material, activity or system
works correctly and actually leads to the expected results ; and
(bb) “wholesale” means sale to a person who purchases
for the purpose of selling again and includes sale to a hospital
or dispensary, or to medical, educational or research institute.
11. In rule 16:-
A. in clause(a) for the Schedule B the following shall be substituted,
namely:-
SCHEDULE-B
CONTENTS
SECTION-I
Premises
1. Location and Surroundings
1.1 Location
1.2 Surroundings
2. Building Layout And Its Pre-Approval
3. Building Design And Construction (General)
3.1 General
3.2 Services
3.3 Protection Against Insects etc
3.4 Surfaces
4. Storage Area
4.1 Capacity
4.2 Design
4.3 Bays
4.4 Quarantine
4.5 Sampling
4.6 Rejected Material
4.7 Special Material
4.8 Packaging Material
4.9 Weighing Area
5. Production Department
5.1 General Facilities
5.2 Dedicated Facilities for Production
5.3 General Requirements for Production
(i) Layout
(ii) Adequacy
(iii) Surfaces
(iv) Services
(v) Drains
(vi) Environmental Controls
(vii) Packaging
(viii) Light
6. Ancillary Area
6.1 Rest Rooms
6.2 Changing Rooms
6.3 Workshop
6.4 Animal House
SECTION-2
EQUIPMENT FOR PRODUCTION
2.1 General
2.2 Layout
2.3 Construction
2.4 Piping
2.5 Tanks
2.6 Filters
2.7 Cleaning Equipment
2.8 Defective Equipment
SECTION-3
QUALITY CONTROL DEPARTMENT
3.1 General
3.2 Laboratories
3.3 Areas
3.4 Facilities
(i) Equipment
(ii) Others
(iii) Written Procedures
(iv) Validation
(v) Storage
SCHEDULE-B
CONTITIONS FOR GRANT OF A LICENSE TO MANUFACTURE DRUGS BY WAY OF
FORMUATION
SECTION-1
Premises
1. Location and surroundings.
1.1 Location : The premises shall be located preferably in an industrial
area and in any case not in any congested residential or commercial
area.
1.2 Surroundings : Premises shall be situated in an environment
that, when considered together with measures to protect the manufacturing
processes, presents minimum risk of causing any contamination of
materials or products. It shall be away from filthy surroundings
and shall not be adjacent to an open sewerage, drain, public lavatory
or any factory which products. It shall be away from filthy surroundings
and shall be adjacent to an open sewerage, drain, public lavatory
or any factory which products a disagreeable or obnoxious odor or
fumes or large quantities of soot, dust or smoke which may contaminate
the drugs being manufactured or adversely affect their quality.
Existing units shall keep the surroundings under their control to
be clean.
1.3 Size: The size of the plot shall be less than 2000 square yards.
2. Building layout and its pre-approval .The building shall be of
adequate size and suitable design and construction in view of the
need for drugs to be manufactured and to suit the operations to
be carries out. The site and layout plan of building shall be not
approval from the central Licensing Board or person authorized by
it in this behalf before starting construction of the building and
any minor subsequent change in the layout plan will be communicated
as and when made with a revised updated layout plan at the time
of renewal of Drug Manufacturing License.
3. Building, design and construction (General) .
3.1 General : The layout and design shall aim at minimization the
risk of errors, facilitate good sanitation and permit effective
cleaning and maintained in order to avoid cross contamination ,
build-up of dust or dirt, and in general , any adverse effect on
the quality of products.
3.2 Services: Electrical supply, lighting, temperature and humidity
controls and ventilation shall be appropriate and such that they
do not adversely effect, directly or indirectly either the pharmaceutical
products during their manufacture and storage, or the accurate functioning
of equipment.
SECTION-4
DOCUMENTATION
4.1 General
4.2 Specifications & Testing Procedures
(i) Reference Books
(ii) Testing Procedures
(iii) Specifications
4.3 Specifications for Starting and Packing Materials
4.4 Specifications For Starting and Packaging Materials
4.5 Mater Formula
4.6 Packing Instructions
4.7 Standard Operating Procedures (SOPs) and Records
4.8 S.O. Ps for Testing
4.9 S.O.Ps for Sanitation
4.10 S.O.Ps Miscellaneous
4.11 Labels
4.12 Batch Processing records
SECTION-5
SANITAON AND HYGIENE
5.1 Sanitation
5.2 Hygiene
3.4 Surfaces : In arrears where raw materials, in-process materials
or drugs are exposed, the following general condition shall apply
to the extent necessary prevent contamination, namely :-
(i) floors, walls, and ceilings/permit easy cleaning, brick , cement
blocks, and other porous materials are sealed;
(ii) floors, walls, ceilings, and other surfaces are hard, smooth,
and free of sharp corners where extraneous material can collect;
(iii) joints are sealed between walls, ceilings and floors;
(iv) pipes, light fittings, ventilation points and other services
do not create surfaces that can not be cleaned; and
(v) screened and trapped floor drains are provided if required.
4. Storage areas.
4.1 Capacity: Storage area shall be properly defined of sufficient
capacity to allow orderly storage of virus categories of materials
and products in quarantine, and released, rejected, returned ,or
recalled products.
4.2 Design: Storage areas shall be designed or adapted to ensue
good storage conditions. In particular, they shall be clean and
dry , suitably lit and maintained within acceptable temperature
limits which should be commensurate with storage requirements of
the drugs. Where special storage conditions are required (e.g.,
controlled temperature and humidity) these shall be provided, checked,
and monitored.
4.3 Bays: Receiving and dispatch bays shall protect materials and
products from the weather, Reception areas shall be designed and
equipped to allow containers of incoming materials to be cleaned
if necessary before storage.
4.4 Quarantine: Well defined quarantine area shall be provided for
the incoming materials, in process materials and finished drugs.
Where quarantine status is ensured by storage in separate areas,
these areas shall be clearly marked and their access restricted
to authorized personnel. Any system replacing the physician quarantine
shall be given equivalent security.
4.5 Sampling: These shall normally be a separate sampling area for
starting materials. If sampling is to be performed in the storage
area, it shall be provided for the storage of rejected, recalled,
or returned materials, or products.
4.6 Rejected Materials: Segregation in a separate area shall be
provided for the storage of rejected, recalled, or returned materials
or products.
4.7 Special Materials : Highly active materials, narcotics, other
dangerous drugs, and substances presenting special risks of abuse
, fire or explosion shall be stored in safe an secure areas.
4.8 Packaging Materials : Printed packing materials are considered
critical to the conformity of the pharmaceutical product to its
labeling, and special attention shall paid to safe and secure storage
of these materials .
4.9 Weighing Area : The weighing of starting materials on the basis
of estimation of yield shall be carried out in separate weighing
areas designed for that use with provisions for dust control. Separate
provisions shall be made for materials posing high risks of contamination,
like steroids and antibiotics especially penicillin.
5. Production Department.
5.1 General Facilities : A Production Department shall be provide
which shall have all necessary facilities including:-
(i) adequate number of appropriately qualified and trained technical
personnel;
(ii) adequate and properly planned areas;
(iii) suitable equipment, instruments and containers for manufacture
including their validation where necessary;
(iv) Clearly defined manufacturing processes shown to be capable
of consistently manufacturing pharmaceutical products of the required
quality and complying with their specifications;
(v) validated critical steps of manufacturing processes;
(vi) Procedure and instructions for working approval by the Quality
Control Department;
(vii) suitable storage places for in process materials;
(viii) adequate number of technically trained and skilled personnel
and equipment for in-process controls;
(ix) skilled operations trained to carry out procedures correctly,
the record of training should be available; and
(x) appropriate air handling system to avoid contamination and cross
contamination.
5.2 Dedicated facilities for production.
Dedicated and self-contained facilities for the production of particular
drugs shall be provide in addition to the general facilities such
as highly sanitizing materials (e.g., penicillin) or biological
preparations (e.g., love microorganisms) or cytotoxic substances
or radiopharmaceutical or veterinary immunological preparations
or sterile products or for that matter such other highly active
pharmaceutical products, antibiotics, hormones as may be identifies
by the Central Licensing Board at any stage in order to minimize
the risk of a serious medical hazard due to cross contamination.
Veterinary products containing ingredients similar to those used
for human health and of the same quality can be manufactured in
the same premises use for manufactured of pharmaceutical products,
however, simultaneously human drugs shall not be manufactured. Non-pharmaceutical
products, technical poisons, such as pesticides shall not be manufactured.
Non-Pharmaceutical products , however , simultaneously human drugs
shall not be manufactured in the same premises already use for the
manufacture of pharmaceutical products. In exceptional cases of
emergency, the principle of campaign working in the same facilities
may be allowed by the Central Licensing Board provided that specific
precautions are taken and the necessary validations are made.
5.3 General requirements for production areas.
(i) Layout: The production area shall be laid out in such a way
as to allow the production to take place in areas connected in a
logical order corresponding to the sequence of the operations and
to the requisite cleanliness levels.
(ii) Adequacy : The adequacy of the working and in process storage
space shall permit the orderly and logical placement of equipment
and materials so as to minimize the risk of confusion between different
pharmaceutical products or their components, to avoid cross contamination,
and to minimize the risk of omission error or working application
of any of the manufacturing or control steps.
(iii) Surfaces : Starting and primary packaging materials and intermediate
or bulk products are exposed to the environment, interior surfaces
(walls, floors, and ceilings) shall be smooth and free from cracks
and open joints shall not shed particulate matter, and shall permit
easy effective cleaning and , if inaccessible, disinfection.
(iv) Services : Pipe work, light fittings, ventilation points and
other services shall be designed and sided to avoid the creation
of recesses that are difficult to clean. As far as possible, for
maintenance purposes, they shall be accessible from outside the
manufacturing areas.
(v) Drains : Drains shall be of adequate size and equipped to prevent
back-flow. Open. Channels shall be avoided.
(vi) Environmental Controls : Production areas shall be effectively
ventilated, with air-control facilities (including control of temperature
and, where necessary, humidity and filtration ) appropriate to the
products handled to the operations undertaken, and to the external
environment. These areas shall be regulatory monitored during production
and non-production periods to ensure compliance with design specifications.
(vi) Packaging : Area (s) for the packing of pharmaceutical products
shall be specifically designed and laid out so as to avoid mix-ups
or cross contamination.
(vii) Light :Production areas shall be well lit, particularly where
visual on-line controls are carried out.
6. Ancillary areas.
6.1 Rest rooms : Rest and refreshment rooms shall be separate from
other areas.
6.2 Changing rooms : Facilities shall be provided for changing and
storing clothes and for washing and toilet purposes which shall
be easily accessible and appropriate for the number of users. Toilets
shall not communicate directly with production or storage areas.
6.3 Workshop : Maintenance workshop shall perfectly be separated
from production areas. Whenever parts and tools are stored in the
production area, they shall be kept in rooms or lockers reserved
for that use.
6.4 Animal houses :Animal houses shall be well isolated from other
areas, with separate entrance (animal access) and air-handing facilities.
SECTION – 2
EQUIPMENT FOR PRODUCTION
2.1 General: The all necessary equipment shall be
provided which shall be so designed, constructed, located installed
and maintained as to suit the operation to be carried out, and the
layout and design of equipment must aim to minimize the risk of
errors and permit effective cleaning and maintenance in order to
avoid cross-contamination, build-up of dust or dirt, and, in general,
any adverse effect on the quality of products.
2.2 Layout: The equipment shall be so laid that: -
(a) Permits it to function in accordance with its intended use.
Parts in contact with raw material, in-process materials, or drugs
are accessible to cleaning or are removable;
(b) Permits cleaning of adjacent areas and does not interfere with
other processing operations, and it also minimizes circulation of
personnel and optimizes flow of material;
(c) Prevents the contamination of drugs by other drugs, by dust,
and by foreign material such as rust, lubricant, and particles coming
from the equipment; and
(d) The base of immovable equipment is adequately sealed along points
of contact with their floor.
2.3 Construction: The equipment shall be so constructed that it
does not add extraneous material to the drug and for that;
(a) the surfaces that come in contact with raw materials, in-process
materials, or drugs are smooth and are made of material that is
non-toxic, corrosion resistant, non-reactive to the drug being manufactured,
and capable of with standing repeated cleaning or sanitizing;
(b) The design is such that the possibility of a lubricant or other
maintenance material contaminating the drug is minimum;
(c) wooden equipment and equipment made of material that is prone
to shed particles or to harbor bacteria do not come in contact or
contaminate raw material, in- process materials, or drugs; and
(d) Chain drives and transmission gears are enclosed or properly
covered.
2.4 Pining: All service piping and devices shall be clearly labeled
to indicate the contents and, where applicable, the direction of
flow and special attention is paid to the provision of non-interchangeable
connection or adopter for dangerous gases and liquids.
2.5 Tanks: Tanks used in processing liquids and ointments are equipped
with fittings that can be dismantled and cleaned and are provided
with appropriate covers.
2.6 Filters: Filter assemblies are designed for easy dismantling.
2.7 Cleaning equipment: Washing and cleaning equipment shall be
provided which shall not be a source of contamination.
2.8 Defective equipment: Defective equipment shall, if possible,
be removed form production and quality control areas, at least,
be clearly labeled as defective.
SECTION – 3
QUALITY CONTROL DEPARTMENT
3.1 General: The Quality Control Department shall be independent
with adequate number of trained personnel and under the authority
of a person who shall be a full time employee.
3.2 Laboratories: Adequate laboratory facilities shall be provided
with necessary equipment and instrument, glassware, chemicals, reagents
etc. suited to testing procedures of drugs to be manufactured.
3.3 Area: The quality control laboratories shall have adequate
areas which shall : -
(i) Be separated from production areas, and the areas where biological,
microbiological or radioisotope test methods are employed shall
be separated from each other;
(ii) Be designed to suit the operations to be carried out in them
and sufficient space shall be given to avoid mix-ups and cross-contamination;
(iii) be so designed so that it takes into account the suitability
of construction materials, fume prevention and ventilation and separate
air handling units and other requirements shall be provided for
biological, microbiological, sterility testing and radioisotope
laboratories;
(iv) have separate room for highly sensitive instruments to protect
these against electrical interference, vibrations, contact with
excessive moisture and other external factors or where there is
need to isolate the instrument; and
(v) Have appropriate facilities to store samples and records.
3.4 Facilities: The quality control laboratory shall have;
(i) Satisfactory equipment required for test and analysis of drugs
intended to be manufactured, protocols for test and analysis of
drugs to be manufactured including their validation where necessary;
(ii) have adequate other facilities and approved procedures for
sampling, inspecting and testing starting materials, packaging materials,
intermediate, bulk, and finished products, and where applicable
for monitoring environmental conditions for good manufacturing practice
purposes;
(iii) Written procedures specifically: -
(a) Validation of methods of manufacture and quality control testing;
(b) Validation of equipment and instruments and cleaning procedures;
(c) Stability testing of the active pharmaceutical substances
and the finished drugs; and
(d) Determining the shelf life of both raw materials and finished
drugs.
(vi) Validations studies conducted for important equipment or instruments,
methods of manufacture and quality control and cleaning procedures
in accordance with predefined protocols. A written report summarizing
results and conclusions shall be available.
(vii) Separate facilities for the bulk storage of volatile and inflammable
materials.
SECTION – 4
DOCUMENTATION
4.1 General: The documents shall: -
(i) be designed and prepared, complying with the relevant parts
of the drug registration approvals.
(ii) be approved, signed, and dated by appropriate authorized
persons and shall not be changed without authorization.
(iii) have unambiguous contents and shall clearly state the title,
nature, and purpose, and they shall be laid out in an orderly fashion
and be easy to check, reproduced documents shall be clear and legible.
4.2 Specifications and Testing Procedures: Following document shall
be available:-
(i) Reference Bodies: Pharmacopoeias, reference standards, reference
spectra, and other reference materials, where necessary.
(ii) Testing Procedures: Validated testing procedures in the context
of available facilities and equipment.
(iii) Specifications: Appropriately authorized and dated specifications,
including tests on identity, content, purity, and quality, for starting
and packaging material and finished products; and where appropriate,
for intermediate or bulk products. Specifications for water, solvents,
and reagents (e.g. acids and bases) used in production shall also
be included.
4.3 Specifications for Starting and Packaging Materials: Specifications
for starting and primary or printed packaging materials shall include,
if applicable: -
(i) the designated name (if applicable, the International Non-proprietary
Name) and internal code reference;
(ii) the reference, if any, to a pharmacopoeia monograph;
(iii) qualitative and quantitative requirements with acceptance
limits; and
(iv) packaging material shall conform to specifications, with
emphasis placed on the compatibility of the material with the drug
product it contains.
4.4 Specifications for Finished Products:
Specification for finished products shall include: -
(i) the designated name of the product and the code reference
where applicable;
(ii) the designated name(s) of the active ingredient(s) (if applicable,
the International Non-proprietary Name)
(iii) the label claim or the reference to the formula.
(iv) a description of the dosage form;
(v) directions for sampling and testing or a reference to procedures;
(vi) the qualitative and quantitative requirements with acceptance
limits;
(vii) the storage conditions and precautions where applicable;
and
(viii) the shelf – life.
4.5 Master formula: A formally authorized master formula shall
exist for each product and batch size to be manufactured, which
shall include;
(i) the name of the product, with a product reference code relating
to its specifications;
(ii) a description of the dosage form, strength of the product,
and batch size; specifications;
(iii) a list of all starting materials to be used (If applicable,
with the International Non-proprietary Name), with the amount of
each described, using the designated name and a reference that is
unique to that material (mention shall be made of any substance
that may disappear in the course of processing) and a reference
number that may disappear in the course of processing) and a reference
number or code number to its quality control testing.
(iv) a statement of the expected final yield with the acceptance
limits, and of relevant intermediate yields where applicable;
(v) a statement of the processing location and the principal equipment
to be used;
(vi) detailed step-wise processing instructions (e.g. checks on
materials, pretreatment, sequence for adding materials, mixing times,
temperatures);
(vii) the instructions for any in-process controls with their limits;
(viii) where necessary, the requirements for storage of the products,
including the container, the labeling, and any special storage conditions;
and
(ix) any special precautions to be observed.
4.6 Packaging Instructions: Formally authorized packaging instructions
shall exist for each product, pack size, and type which shall normally
include, or made reference to
(i) the name of the product;
(ii) a description of its pharmaceutical for, strength and method
of application where applicable;
(iii) the pack size expressed in terms of the number, weight, or
volume of the product in the final container;
(iv) a complete list of all the packaging materials required for
a standard batch size, including quantities, sizes, and types, with
the code or reference number relating to the specifications for
each packaging materials;
(v) where appropriate, an example or reproduction of the relevant
printed packaging materials and specimens, indicating where the
batch number and expiry date of the product have been marked;
(vi) special precautions to be observed, including a careful examination
of the packaging area and equipment in order to ascertain the line
clearance before operations being;
(vii) a description of the packaging operations, including any significant
subsidiary operations, and equipment to be used; and
(viii) details of in-process controls with instructions for sampling
and acceptance limits.
4.7 Standard Operating Procedures and Records. There shall be standard
operating procedures for : -
(i) the receipt of each delivery of starting material and primary
and printed packaging material;
(ii) the international labeling, quarantine, and storage of starting
materials, packaging materials, and other materials, as appropriate;
(iii) each instrument and piece of equipment. These shall be placed
in close proximity to the equipment;
(iv) sampling, which specify the person(s) authorized to take samples,
and the sampling instructions shall included;
(a) the method of sampling and the sampling plan;
(b) the equipment to be used;
(c) any precautions to be observed to avoid contamination of the
material or any deterioration in its quality;
(d) the amount of sample to be taken;
(e) instructions for any required sub-division of the samples;
(f) the type of sample container to be used, and whether they are
for aseptic sampling or for normal sampling; and
(g) any specific precautions to be observed, especially in regard
to the sampling of sterile or noxious material;
(v) describing the details of the batch (lot) numbering system,
with the objective of ensuring that each batch of intermediate,
bulk, or finished product is identified with a specific batch number;
(vi) for batch numbering that are applied to the processing stage
and to the respective packaging stage shall be related to each other;
(vii) for batch numbering shall assure that the same batch numbers
will not be repeatedly used; this applies also to reprocessing.
4.8 There shall be written procedures for testing materials and
products at different stage of manufacture, describing the methods
and equipment to be used. The tests performed shall be recorded
and shall include: -
(a) name of the material or drug and, where applicable, dosage
form;
(b) batch number and, where appropriate, the manufacturer and /or
supplier;
(c) references to the relevant specifications and testing procedures;
(d) test results, including observations and calculations, and reference
to any specifications (limits);
(e) dates of testing;
(f) initials of the persons who performed the testing;
(g) initials of the persons who verified the testing and the calculations.
Where appropriate;
(h) a clear statement of release or rejection and the dated signature
of the designated responsible person.
4.9 There shall be written procedures assigning responsibility
for sanitation and describing in sufficient detail the cleaning
schedules, methods, equipment, and materials to be used and facilities
to be cleared and such written procedures shall be followed.
4.10 Written standard operating procedures and the associated records
of actions taken shall be available, for: -
(a) equipment assembly and validation;
(b) analytical apparatus and calibration;
(c) maintenance, cleaning and sanitization;
(d) personnel matters including qualifications, training, clothing,
hygiene;
(e) environmental monitoring;
(f) pest control;
(g) complaints;
(h) recalls;
(i) returns;
4.11 Labels:
4.11.1 Labels firmly affixed or security attached to containers,
equipment or working areas shall be clear and unambiguous and shall
indicate the status like “quarantined” “accepted”
“rejected” “clean”, etc.
4.11.2 All finished drugs shall be labeled in accordance with the
approval of Registration Board and with at least the following information:
-
a) the name of the drug;
b) a list of the active ingredients, showing the amount of each
present, and a statement of the net contents, e.g. number of dosage
units, weight or volume;
c) the batch number assigned by the manufacturer;
d) the expiry date;
e) any special storage conditions or handling precautions that my
be necessary;
f) direction for use, and warnings and precautions that may be necessary;
and
g) the name and address of the manufacturer or the company or the
person responsible for placing the drug on the market.
4.11.3 The label or accompanying document of reference standards
shall indicate concentration, date of manufacture, expiry date,
date the closure is first opened and storage conditions, where appropriate.
4.12 Batch Processing Records:
4.12.1 A Batch Processing Record shall be maintained for each batch
processed. It shall be based on the relevant portions of the approved
Master Formula and Processing Instructions.
4.12.2 Before starting any processing a check shall be performed
and recorded that the equipment and work station are clear of previous
products, documents or materials not required for the planned process,
and that equipment is clean and suitable for use.
4.12.3 During processing, the following information shall be recorded
and, after completion, the record shall be dated and signed in agreement
by the person responsible for the processing operations:
a) the name of the drug;
b) the number of the batch being manufactured;
c) dates and time of commencement of significant intermediate stage
and of completion of production;
d) initials of the operator of different significant steps of production
and where appropriate, of the person who checked each of these operations
(e.g. weighing);
e) the batch number and / or analytical control number as well as
the quantities of each starting material actually weighed (including
the batch number and amount of any recovered or reprocessed material
added);
f) any relevant processing operation or event and major equipment
used;
g) a record of the in-process controls and the initials of the person(s)
carrying them out, and the results obtained;
h) the amount of drug obtained at different stages of manufacture
(yield) explaining any significant deviations fro the expected yield;
i) notes on special problems including details, with signed authorization,
for nay deviation from the Master Formula.
SECTION – 5
SANITATION AND HYGIENE
5.1 Sanitation: A written sanitation
program shall be available which will include instructions on the
sanitary production of drugs and the handling of materials used
in the production of drugs and, in particular, indicating the following
cleaning procedures for the premised and the equipment used in the
production of drug, namely: -
(i) cleaning requirements applicable to all production areas of
the plant, with emphasis on manufacturing areas that require special
attention;
(ii) cleaning requirements applicable to processing equipment;
(iii) cleaning intervals;
(iv) cleaning materials, their concentration, and the equipment
to bused;
(v) responsibilities of outside contractors, if any;
(vi) disposal procedures for waste material and debris;
(vii) pest control measures;
(viii) precautions required to prevent contamination of a drug when
rodenticides, insecticides, and fumigation agents are used;
(ix) microbial and environmental monitoring procedures and limits
in areas where susceptible products are manufactured; and
(x) the personnel responsible for carrying out cleaning procedures.
5.2. Hygiene:
5.2.1 Minimum requirements of health, hygienic behavior and clothing
for personnel shall be available in writing in order to ensure the
clean and sanitary production of the drug.
5.2.2 No person who is affected with or is a carrier of a disease
in a communicable for, or has an open lesion on any exposed surface
of the body shall be employed for areas where a drug during any
stage of its production is exposed.
5.2.3 Minimum requirements of health shall be available in in writing
and shall provide for : -
(j) pre-employment medical examination;
(ii) assessment of an employee’s health prior to return to
his place of employment following illness involving a communicable
disease;
(iii) action to be taken in the event of a positive diagnosis or
a case suspected of being hazardous to consumers of the products;
and
(iv) routine supervisory check system of employees.
5.2.4 The hygiene program shall clearly define clothing requirements
and hygiene procedures for company personnel and visitors including
the following : -
(i) Where a potential for the contamination of a raw material,
in-process material, or drug exists, individuals shall wear clean
clothing and protective covering.
(ii) Eating, smoking, or any unhygienic practice shall not be permitted
in production areas.
(iii) Requirements concerning personal hygiene, with emphasis on
hand hygiene.
(iv) Requirements concerning cosmetics and jewelry worn by employees.
B in clause (c), in sub-clause (i) : -
(a) for the words “ twelve months” the words “three
years” shall be substituted; and
(b) for the word “drug” the words “type of drugs
to be manufactured” shall be substituted; and
C in clause (e), for the words “sufficient experience in
testing of drugs” the words “three years experience
in testing of types of drugs intended to be manufactured”
shall be substituted;
III. in rule 20, in clause (a), for the “Schedule B II”
the following new Schedule B II shall be substituted, namely : -
SCHEDULE B-II
GOOD MANUFACTURING PRACTICES (GMPS) FOR
LICENSE TO MANUFACTURE BY WAY OF FROMULATION
CONTENTS
PART – I
GENERAL CONDITIONS
SECTION – I
1 Responsibility of licensee for drugs fitness for use
SECTION – 2
2. Quality assurance system
SECTION – 3
3. Quality control
3.1 Quality Control Department
3.2 Basic requirements
3.3 Control procedures.
3.1 General
3.3.2 Sampling
3.3.3 Test requirement for starting and packaging materials
3.3.4 Test requirement for in-process controls
3.3.5 Test Requirement for Finished Products
3.3.6 Production record/batch review
3.3.7 Stability studies
3.4 Self inspection
3.4.1 General
3.4.2 Items for self inspection
3.4.3 Self inspection team
3.4.4 Frequency of self inspection
3.4.5 Self inspection report
3.5 Quality Audit
3.5.1 Audit by independent specialist
3.5.2 Supplier’s audits
3.5 Complaints
3.6.1 Review of complaints
3.6.2 Person authorized
3.6.3 Written procedures
3.6.4 Recording defects and investigation
3.6.5 Investigation
3.6.6 Follow-up action
3.6.7 Recording measures
3.6.8 Review for Reviewing Problem
3.7 Product recalls
3.7.1 System
3.7.2 Authorized person
3.7.3 Written procedures
3.7.4 Recall with promptness
3.7.5 Distribution records
3.7.6 Recording and progress
3.7.7 Evaluation
3.7.8 Storage of recalled drugs
3.7.9 All concerned to be informed
SECTION – 4
4. Personnel
4.1 General
4.2 Written duties
4.3 GMP awareness
4.4 Prohibition of unauthorized person
4.5 Duties of Heads of Departments
4.6 Duties of Production Incharges
4.7 Duties of Quality Control Incharges
4.8 Training
4.8.1 Written programme
4.8.2 Training appropriate to duties
4.8.3 Specific training
4.8.4 Understanding concepts
4.8.5 Visitor and untrained personnel discouraged
4.9 Personal hygiene
4.9.1 Health examination
4.9.2 Practices in personal hygiene
4.9.3 Illnesses
4.9.4 Reporting health problems
4.9.5 Avoiding direct contact with materials
4.9.6 Appropriate clothing and covering
4.9.7 Foods and drinks prohibited
SECTION – 5
GOOD PRACTICES IN MANUFACTURING PROCESSING
5.1 General responsibility of licensee
SECTION – 6
MATERIALS
6.1 Material general
6.1.1 Quarantine
6.1.2 Appropriate storage
6.2 Starting materials
6.2.1 Purchase
6.2.2 Purchase from producer or established supplier
6.2.3 Checking of containers
6.2.4 Damaged container
6.2.5 Delivery from different batches
6.2.6 Labeling
6.2.7 Identity of contents
6.2.8 Released materials to be used
6.2.9 Correct dispensing
6.2.10 Checking
6.2.11 Labeling
6.3 Packaging materials
6.3.1 Purchase
6.3.2 Printed materials
6.3.3 Reference numbers
6.3.4 Obsolete materials
6.3.5 Checking before delivery
6.4 Intermediate and bulk products
6.4.1 Storage
6.4.2 Handling
6.5 Finished pharmaceutical products
6.5.1 Quarantine
6.5.2 Release
6.6 Rejected and recovered materials
6.6.1 Storage and disposal
6.6.2 Reprocessing
6.6.3 Batch recovers
6.6.4 Additional testing of reprocessed material
6.7 Recalled and returned products
6.7.1 Recalled products
6.7.2 Returned goods
6.8 Reagents and culture media
6.9 Reference standards
6.9.1 Testing prepared reference standard
6.9.2 Use
6.9.3 Working standards
6.9.4 Storage
6.10 Waste materials
6.10.1 Storage
6.10.2 Disposal
6.11 Miscellaneous
SECTION – 7
7.1 Processing operations
7.1.1 General
7.1.2 Material handling
7.1.3 Avoiding deviation
7.1.4 Yield checks
7.1.5 Avoiding mix-ups
7.1.6 Labeling
7.1.7 Unauthorized entry prohibited
7.1.8 In price controls
7.2 Prevention of cross-contamination and bacterial
Contamination in production
7.2.1 Precautions against dust
7.2.2 Measures against contamination
7.2.3 Cross contamination checks
7.2.4 Microbiological monitory
7.3 Processing operations intermediate and bulk
Products
7.3.1 Pre-Processing cleanliness checks
7.3.2 In-process controls
7.3.3 Defective equipment
7.3.4 Cleaning containers
7.3.5 Yield deviations
7.3.6 Product pipelines
7.3.7 Water pipes
7.3.8 Equipment calibration
7.3.9 Repair or maintenance
7.4 Packaging operations
7.4.1 Avoiding mix-ups
7.4.2 Pre-packaging checks
7.4.3 Labeling packaging line
7.4.4 Process continuity
7.4.5 Printing operation checks
7.4.6 Label verification
7.4.7 Resistant printing on labels
7.4.8 On-line packaging checks
7.4.9 Product re-introduction on packaging line
7.4.10 Discrepancies to be investigated
7.4.11 Destruction of un-used packaging materials
SECTION – 8
Sanitation and hygiene
SECTION – 9
Validation
9.1 General
9.2 Process validation
9.2.1 Validation of critical processes
9.2.2 Validation of new master formula
9.2.3 Validation of equipment or materials
SECTION – 10
10.1 Documents
10.1.1 Maintenance of documents
10.1.2 Recording actions
10.1.3 Documentation system
10.1.4 Status identification
10.1.5 Product labeling
10.1.6 Reference standards identification
10.1.7 Specification approvals
10.1.8 Revision of specification
10.1.9 Packaging material specification
10.1.10 Starting material re-assay
10.2 Specification for intermediate and bulk products
10.3 Batch processing records
10.3.1 General
10.3.2 Checking work station
10.3.3 Recording process operation
10.4 Batch packaging records
10.4.1 General
10.4.2 Pre-packaging line checks
10.4.3 Recording packaging Operation
10.4.4 Recording packaging batch numbers
10.4.5 Analytical records
10.4.6 Finished product release procedure
10.4.7 Recording batch distribution
10.4.8 Standard operating procedures
10.4.9 Equipment logbooks
10.4.10 Equipment utilization records
PART – II
ADDITIONAL CONDITIONS FRO MANUFACTURE OF
STERILE PRODUCT
SECTION -1
General
1.1 Air Classification System for manufacture of sterile products
Manufacture of sterile preparations
2.1 manufacturing operations
2.2 Terminally sterilized products
2.3 Products sterilized by filtration
2.4 Products manufactured under aseptic conditions
3 Personnel
3.1 General
3.2 Personnel training
3.3 Entry restricted
3.4 Hygiene and cleanliness
3.5 Use of protective garments
3.6 Clothing requirements
3.7 Protective garments in grade B room
3.8 Washing of clothing
3.9 Prohibitions
SECTION – 2
4 Maintenance of clean area
4.1 General
4.2 Airlock system
4.3 Air supply system
4.4 Maintenance of equipment
4.5 Water supply
SECTION – 3
5 Equipment maintenance
5.1 Documentation
SECTION – 4
6 Sanitation
6.1 Procedure
6.2 Use of disinfectants and detergents
6.3 Fumigation
6.4 Monitoring of clean areas
SECTION – 5
7 Processing
7.1 Precautions against contamination
7.2 Preparation of live organisms
7.3 Simulation of aseptic operations validation
7.4 Monitoring water supply sources
7.5 Activities in clean areas kept minimum
7.6 Care of stating materials
7.7 Care against fibers
7.8 Care after final cleaning of materials
7.9 Interval between operations to be minimal
7.10 Sterilization of gases used
7.11 Disburden to be minimal
7.12 Asepsis of articles in clean areas
7.13 New processes to be validated
SECTION – 6
8 Sterilization
8.1 General
8.2 Validation
8.3 Suitability of process
8.4 Care for biological indicates
8.5 Sterilized non-sterilized products
9 Sterilization by heat
9.1 Recording sterilization cycle
9.2 Sufficient time allowed to reach required temperature
9.3 Precautions drugging cooling
10 Sterilization by moist heat
10.1 General
10.2 Wrapping materials
11 Sterilization by dry heat
12 Sterilization by radiation
12.1 General
12.2 Outside contractor
12.3 Measurement of radiation
12.4 Validation
12.5 Handling procedures
13 Sterilization by ethylene oxide
13.1 General
13.2 Ensure contact between gas and microbial cells
13.3 Equilibrium with humidity and temperature
13.4 Monitoring each cycle
13.5 Biological indicators
13.6 Record maintenance
13.7 Validation
14 Filtration of pharmaceutical products that can not
Be sterilized in the final container
14.1 General
14.2 Using double filter layer
14.3 Eliminate fibers
14.4 Checking integrity of filters
14.5 Frequency of use of filter
14.6 Filter safety
15 Finishing of sterile products
15.1 General
15.2 Use of vacuum
15.3 Inspection of containers
16 Quality control
16.1 Sterility testing
16.2 Sterility test as the last measures
16.3 Monitoring end toxin
SCHEDULE –II
GOOD MANUFACTURING PRACTICES (GMPS) FOR LICENSE TO
MANUFACTURE BY WAY OF FROMULATION
PART – I
GENERAL CONDITIONS
SECTION – 1
1. Responsibility of licensee for drug’s fitness for use.
The licensee shall assume the responsibility for
the quality of the furs manufactured by it to ensure that they are
fit for their intended use, comply with the requirements of the
Ordinance and rules made there under and do not place patients at
risk due to inadequate safety, quality or efficacy. To achieve the
quality objective reliably, there shall be a comprehensively designed
and correctly implemented system of quality assurance incorporating
good manufacturing practices nod quality control. It shall be fully
documented and its effectiveness monitored. All parts of the quality
assurance system shall be adequately staff with competent personnel
and shall have suitable and sufficient premises, equipment, and
facilities.
SECTION – 2
2. Quality assurance system.
The licensee shall have a system of quality assurance appropriate
to the manufacture of drugs which shall ensure that: -
(a) drugs are designed and developed in a way that takes into account
the requirements of good manufacturing practices and other associated
codes as may be notified form time to time;
(b) production and control operations are clearly specified in a
written form and good manufacturing practices requirements are adopted
and followed;
(c) managerial responsibilities are clearly specified in job description;
(d) arrangements are made for the manufacture, supply, and use of
the correct starting and packaging materials;
(e) all necessary controls on starting materials, intermediate products,
and bulk products and other in process controls, calibrations and
validations are carried out;
(f) the finished products are correctly processed and checked, according
to the defined procedures;
(g) finished drugs are not sold or supplied before the authorized
person(s) has certified that each production batch has been produced
and controlled in accordance with the requirements of the good manufacturing
practices and the relevant rules made under the Ordinance relevant
to the production, control and release of drugs as well as of conditions
of registration;
(h) satisfactory arrangements exist to store in appropriate storage
conditions;
(i) there is a procedure for self inspection and or quality audit
at appropriate intervals that regularly reviews the effectiveness
and applicability of the quality assurance system and that such
a procedure is followed; and
(j) a system exist in the form of written Standard Operating Procedures
according to which complaints about marketed products are examined,
the causes of quality defects investigated, and appropriate measure
taken in respect of the defective products and to prevent recurrence
and that system is followed.
SECTION – 3
3. Quality control.
3.1. Quality control department: The licensee shall maintain and
satisfactory run its quality control department which is independent
of other departments and under the authority of a person with the
required qualifications and experience and with adequate facilities
to ensure that all the quality control arrangements are effectively
and reliably carried out.
3.2. Basic requirements: The basic requirements to be met for quality
control shall be as follows: -
(a) During the period of validity of license, adequate facilities,
trained personnel and approved procedures are available for sampling,
inspecting, and testing stating materials, packaging materials,
and intermediate, bulk, and finished products, and where appropriate
for monitoring environmental conditions for good manufacturing practices
purposes;
(b) Samples of starting materials, packaging materials, intermediate
products, bulk products and finished products are taken by methods
and personnel approved of by the quality control department;
(c) Test methods are validated;
(d) Records are made manually and or by recording instruments demonstrating
that all the required sampling, inspecting, and testing procedures
have actually been carried out and that any deviation has been fully
recorded and investigated;
(e) The finished products contain ingredients complying with the
qualitative and authorization, the ingredients shall be of the required
purity, in their proper container, and correctly labeled;
(f) Record are made of the results of inspecting and testing materials
and intermediate, buck, and finished precuts against specification
and product documentation and an assessment of deviations from specified
procedures;
(g) No batch of product is released for sale prior to certification
by the authorized person(s) that it is in accordance with the requirements
of the rules;
(h) Sufficient samples of starting materials and products are retained
to permit future examination of the product if necessary and the
retained product is kept in its final pack unless the pack is exceptionally
large; and
(i) All quality control procedures are established, validated and
implemented; the reference standard for substances are evaluated,
maintained, and stored, correct labeling of containers of materials
and product is ensured; the stability of the active pharmaceutical
ingredients and products is monitored, complaints related to the
quality of the product are investigated and environmental monitoring
is conducted. All these operations shall be carried out in accordance
with written procedures and where necessary, recorded, provided
that the Central Licensing Board may allow other arrangements if
it is considered so necessary for an effective quality control system
of the licensee.
3.3 Control Procedures.
3.3.1 General: All tests and analysis and analysis conducted shall
be in accordance with the instructions given in the relevant written
test procedures. The result shall be checked by the supervisor before
the material or product is released or rejected.
3.3.2 Sampling: The samples shall: -
(a) be representative of the batches of material from which they
are taken and in accordance with approved written procedure;
(b) be taken in a manner so as to avoid contamination or other adverse
effects on quality, and the containers that have been sampled shall
be marked accordingly and carefully resealed after sampling;
(c) be taken with care to guard against contamination or mix-up
of, or by, the material being sampled, all sampling equipment that
comes into contact with the material shall be clean, and some particularly
hazardous or potent materials may require special precautions;
(d) be taken with equipment which shall be cleaned and, if necessary,
sterilized before and after each use and stored separately from
other laboratory equipment; and
(e) bear a label indication: -
(i) the name of the sampled material;
(ii) the batch or lot number;
(iii) identify the container from which the sample has been taken
(iv) the signature of the person who has taken the sample; and
(v) the date of sampling.
3.3.3 Testing requirement for starting and packaging materials.
(i) Test before use: Before releasing a starting or packaging material
for use, the quality control manager shall ensure that the materials
have been tested for conformity with specifications for identity,
strength, purity, and other quality parameters.
(ii) Identity from each container: An identity test shall be conducted
on a sample from each container of starting material.
(iii) Examination of each batch: Each batch (lot) of printed packaging
materials shall be examined following receipt.
3.3.4 Test requirement for in-process controls.
Records of testing: In-process control records shall be maintained
and form a par------ of the batch records.
3.3.5 Test requirements for finished products:
(i) Testing each batch: For each batch of drug product, there shall
be an appropriate laboratory determination of satisfactory conformity
to its finished product specifications prior to release.
(ii) Rejection of failed products: Products failing to meet the
established specifications or any other relevant quality criteria
may be revalidated and shall be rejected if they do not qualify
revalidation protocols.
(iii) Reprocessing: Reprocessing may be performed, if feasible,
but the reprocessed product shall meet all specifications and other
quality criteria prior to its acceptance and release.
3.3.6 Production record and batch review.
(i) Review of Records: Production and control records shall be reviewed
and any divergence or failure of a batch to meet its specifications
shall be thoroughly investigated, the investigation shall, if necessary,
extend to other batches of the same product and other products that
may have been associated with the specific failure or discrepancy,
and a written record of the investigation shall be made and shall
include the conculsio0n and details of follow-up action.
(ii) Retention of Samples: Retention samples from each batch of
finished product shall be kept for at least one year after the expiry
date. Finished products shall usually be kept in their final packaging
and stored under the recommended conditions. If exceptionally large
packages are produced, smaller samples might be stored in appropriate
container. Samples of active starting materials shall be retained
for five years. Other starting materials (other than solvents, gases,
and water) shall be retained for minimum of two years if their stability
allows; Retention samples of materials and products shall be of
a size sufficient to permit at least tow full re-examinations.
3.3.7 Stability studies:
(i) The quality control department shall: -
(a) evaluate the quality and stability of finished pharmaceutical
products and, of starting materials and intermediate products; and
(b) establish expiry dates and shelf-life specifications on the
basis of stability tests related to storage conditions.
(ii) A written program for ongoing stability determination shall
be developed and implemented to include elements such as: -
(a) a complete description of the drug involved in the study;
(b) the complete testing parameters and methods describing all tests
for potency, purity, and physical characteristics and documented
evidence that these test indicate stability.
(c) Provision for the inclusion of a sufficient number of batches;
(d) The testing of each drug;
(e) Provision for special storage conditions;
(f) Provision for adequate sample retention; and
(g) A summary of all the data generated, including the evaluation
and the conclusions of the study.
(iii) Stability of the finished product shall be evaluated and documented
prior to marketing and following and significant changes in the
processes, equipment, primary packaging materials, etc.
3.4 Self-inspection:
3.4.1 General: The licensee shall conduct repeated self inspection
with a view to evaluate its own compliance with good manufacturing
practices in all aspects of production and quality control; The
self inspection program shall be designed to detect any shortcomings
in the implementation of good manufacturing practices and to recommend
the necessary corrective actions; Self inspections shall be performed
routinely, and may be, in addition, performed on special occasions,
e.g. in the case of product recalls or repeated rejections or when
an inspection by the Central Licensing Board is required; The team
responsible for self inspection shall consist of personnel who can
evaluate the implementation of good manufacturing practices objectively;
all recommendations for corrective action shall be implemented;
The procedure for self-inspection shall be documented, and there
shall be an effective follow-up program.
3.4.2 Items for self inspection: Written instructions for self inspection
shall be established to provide a minimum and uniform standard of
requirements and shall include questionnaires on good manufacturing
practices requirements covering at least the following items, namely;
(a) personnel;
(b) premises including personnel facilities;
(c) maintenance of buildings and equipment;
(d) storage of starting materials and finished products;
(e) equipment;
(f) production and in-process controls;
(g) quality control;
(h) documentation;
(i) sanitation and hygiene;
(j) validation and verification programs;
(k) calibration of instruments or measurement systems;
(l) recall procedures;
(m) complaints management;
(n) labels control; and
(o) results of previous self-inspections and any corrective steps
taken.
3.4.3 Self-inspection team: Management shall appoint a self-inspection
team of members from inside or outside the company who are expert
in the field of inspection and familiar with good manufacturing
practices.
3.4.4 Frequency of self-inspection: The frequency at which self-inspections
are conducted may depend on company requirements but it shall be
at least once every year.
3.4.5 Self-inspection report: A report shall be made at the completion
of self-inspection which shall include: -
(a) self-inspection results;
(b) evaluation and conclusion; and
(c) recommended corrective actions.
3.4.6 Follow-up actions: The company management shall evaluate both
the self-inspection report and the corrective actions as are necessary.
3.5 Quality audit:
3.5.1 Audit by independent specialist: It may be useful to supplement
self-inspection with a quality audit which consists of an examination
and assessment of all or part of a quality system with the specific
purpose of improving it; a quality audit is usually conducted by
outside or independent specialists or a tem a designated by the
management for this purpose; such audits may also be extended to
suppliers and contractors.
3.5.2 Supplier’s audits: The quality control department shall
have responsibility together with other relevant departments for
approving suppliers who can reliably supply starting and packaging
materials that meet established specifications.
3.6 Complaints:
3.6.1 Review of complaints: All complaints and other information
concerning potentially defective products must be carefully reviewed
according to written procedures.
3.6.2 Person authorized: A person responsible for handling the complaints
and deciding the measures to be taken shall be designated, together
with sufficient supporting staff to assist him and if this person
is different from the authorized person, the latter shall be made
aware of any complaint, investigation, or recall.
3.6.3 Written procedures: There shall be written procedures describing
the action to be taken including the need to consider a recall,
in the case of a complaint concerning a possible product defect.
3.6.4 Recording defects and investigation: Any complaint concerning
a product defect shall be recorded with all the original details
and thoroughly investigated; The person responsible for quality
control shall normally be involved in the study of such problems.
3.6.5 Investigation: If a product defect is discovered or suspected
in a batch, consideration shall be given to whether other batches
shall be checked in order to determine whether they are also affected;
in particular, other batches that may contain reprocessed product
from the defective batch shall be investigated.
3.6.6 Follow up action: Where necessary, appropriate follow-up action,
possibly including product recall, shall be taken after investigation
and evaluation of the compliant.
3.6.7 Recording measures: All the decisions and measures taken as
a result of a complaint shall be recorded and referenced to the
corresponding batch record.
3.6.8 Review for recurring problems: Complaint record shall be regularly
reviewed for any indication of specific or recurring problems that
require attention.
3.7 Product recalls.
3.7.1 System: There shall be a system to promptly and effectively
recall from the market the products known or suspected to be defective.
3.7.2 Authorized person: A person responsible for the execution
and coordination of recalls shall be designated, as well as sufficient
staff to handle all aspects of the recalls with the appropriate
degree of urgency; this person shall normally be independent of
the sales and marketing organization; if this person is different
from the authorized person the latter shall be jade aware of any
recall operation.
3.7.3 Written procedures: There shall be established written procedures,
regularly checked and updated for the organization of any recall
activity. Recall operations shall be capable of being initiated
promptly at least down to the level of the health institutions and
all sale channels including whole sale and where possible retail
sale and a public notice if required.
3.7.4 Recall with promptness: All competent authorities to whom
a given product may have been distributed shall be promptly informed
of any intention to recall the product because it is, or was suspected
of being, defective.
3.7.5 Distribution records: The distribution records shall be readily
available to the person(s) responsible for recalls, and they shall
contain sufficient information on wholesalers and directly supplied
customers(including, for exported products, those who have received
samples for clinical tests and medical samples) to permit and effective
recall.
3.7.6 Recording of progress: The progress of the recall process
shall be recorded and a final report issued, including a reconciliation
between the delivered and recovered quantities of the products.
3.7.7 Evaluation: The effectiveness of the arrangements for recalls
shall be evaluated from time to time.
3.7.8 Storage of recalled drugs: An instruction shall be included
to store recalled products in a secure segregated area while their
fate is decide.
3.7.9 All concerned to be informed: The Central Licensing and Registration
Boards and other concerned government authorities shall be immediately
informed if it is intended to recall product(s) or if a product
has been recalled. Effective system shall be maintained to inform
the doctors, pharmacists and public of the recalled products.
SECTION - 4
Personnel
4.1 General: The licensee shall provide: -
(a) sufficient qualified personnel to fulfill all its responsibilities
required under these rules; and
(b) organization chart.
4.2 Written duties: All responsible staff shall have their specific
duties recorded in written descriptions and adequate authority to
carry out their responsibilities. There shall be no gaps or unexplained
overlaps in the responsibilities of personnel concerned with the
application of good manufacturing practices. Individual responsibilities
shall be clearly understood by the individuals concerned;
4.3 Good manufacturing practices awareness: All personnel shall
be aware of the principles of good manufacturing practices that
affect them and receive initial and continuing training, including
hygiene instructions, relevant to their needs.
4.4 Prohibition of unauthorized persons: Steps shall be taken to
prevent unauthorized people from entering production, storage, and
quality control areas, and personnel who do not work in these areas
shall not use them as a passageway.
4.5 Duties of heads of departments: The heads of the production
and quality control departments may have shared, or jointly exercised
the following responsibilities relating to quality, namely: -
(a) the authorization of written procedures and other documents,
including amendments;
(b) the monitoring and control of the manufacturing environment;
(c) plant hygiene;
(d) process validation and calibration of analytical apparatus;
(e) training, including the application and principles of quality
assurance;
(f) the approval and monitoring of suppliers of materials;
(g) the approval and monitoring of contract manufacturers;
(h) the designation and monitoring of storage conditions for materials
and product;
(i) the retention of records;
(j) the monitoring of compliance with good manufacturing practices
requirements;
(k) the inspection, investigation, and taking of samples in order
to monitor factors that may affect product quality.
4.6 Duties of production in charge: The head of the production department
may have the following responsibilities, namely: -
(a) to ensure that products are produced and stored according to
the appropriate documentation in order to obtain the required quality;
(b) to approve the instructions relating to production operations
including the in process controls, and to ensure their strict implementation;
(c) to ensure that the production records are evaluated and signed
by a designated person before they are made available to the quality
control department;
(d) to check the maintenance of the department, premises, and equipment;
(e) to ensure that the appropriate process validations and calibrations
of control equipment are performed and recorded and the reports
made available; and
(f) to ensure that the required initial and continuing training
of production personnel is carried out and adapted according to
need.
4.7 Training:
4.8.1 Written programmed: The training shall be provided in accordance
with a written program for all the personnel whose duties required
them to work in the production areas, as the case may be, in the
control laboratories (including the technical, maintenance, and
cleaning personnel), and for other personnel whose activities could
affect the quality of the product.
4.8.2 Training appropriate to duties: Besides basic training on
the theory and practice of good manufacturing practices, newly recruited
personnel shall receive training appropriate to the duties assigned
to them, continuing training shall also be given, and its practical
effectiveness shall be periodically assessed, training programs
shall be available, approved by the head of either production or
quality control, as appropriate, and training records shall be kept.
4.8.3 Specific training: Personnel working in areas where contamination
is a hazard, such as clean areas or areas where highly active, toxic,
infectious, or sensitizing materials are handled, shall be given
specific training.
4.8.4 Understanding concepts: The concept of quality assurance and
all the measures capable of improving its understanding and implementation
shall be fully discussed during the training sessions.
4.8.5 Visitors or untrained personnel discouraged: Visitors or untrained
personnel shall be discouraged entry into the production and quality
control areas.
4.9 Personal hygiene:
4.9.1 Health examination: All personnel, prior to and during employment,
as may be appropriate, shall undergo health examinations and personnel
conducting visual inspections shall also undergo periodic eye examinations.
4.9.2 Practices in personal hygiene: All personnel shall be trained
in the practices of personal hygiene, a high level of personal hygiene
shall be observed by all those concerned with manufacturing processes,
personnel shall be instructed particularly to wash their hands before
entering productions areas, and signs to this effect shall be pasted
and instructions observed.
4.9.3 Illnesses: Any person shown at any time to have an apparent
illness or open lesions that may adversely affect the quality of
products shall not be allowed to handle starting materials, packaging
materials, in process materials, or drug products until the condition
is no longer judge to be a risk.
4.9.4 Reporting health problem: All employees shall be instructed
and encouraged to report to their immediate supervisor any conditions,
relating to plant, equipment, or personnel, that they consider may
adversely affect the products.]
4.9.5 Avoiding direct contact with materials: Direct contact shall
be avoided between the operator’s hands and starting materials,
primary packaging materials, and intermediate or bulk product.
4.9.6 Appropriate clothings and covering: To ensure protection of
the product form contamination, personnel shall wear clean body
coverings appropriate to the duties they perform, including appropriate
hair covering, and used clothes, if re-usable, shall be stored in
separate closed containers until properly laundered and, if necessary,
disinfected or sterilized.
4.9.7 Foods and drinks prohibited: Smoking eating, drinking, chewing,
and keeping plants, food, drink smoking material, and personal medicines
shall not be permitted in production, laboratory, and storage areas
or in any other areas where they might adversely influence product
quality.
SECTION – 5
GOOD PRACTICES IN MANUFACTURING PROCESSING.
5.1 General responsibility of licensee: The licensee shall follow
Good Manufacturing Practices in production of drugs under which
it shall be ensured that: -
(a) all manufacturing processes which shall be defined are systematically
reviewed in the light of experience, and shown to be capable of
consistently manufacturing pharmaceutical products of the required
quality that comply with their specifications;
(b) critical steps of manufacturing processes and any significant
changes made to the processes are validated;
(c) all necessary facilities are continued to be made available,
including:-
(i) appropriately qualified and trained personnel;
(ii) adequate premises and space;
(iii) suitable equipment and services;
(iv) correct materials, containers, and labels;
(v) approved procedures and instructions;
(vi) suitable storage and transport; and
(vii) adequate personnel, laboratories, and equipment of in-process
controls under the responsibility of the production management.
(d) instructions and procedures are written in clear and unambiguous
language, specifically applicable to the facilities provided and
followed in letter and spirit;
(e) operators receive training and refresher courses at regular
intervals to carry out procedures correctly, and records of such
training are maintained;
(f) records are made, manually and or by recording instruments,
during manufacture to show that all the steps required by the defined
procedures and instructions have in fact been taken and that the
quantity and quality of the product are as expected, and any significant
deviations are fully recorded and investigated;
(g) records covering manufacture and distribution, which enable
the complete history of a batch to be traced, are retained in a
comprehensible and accessible form;
(h) the proper storage and distribution of the products minimizes
any risk to their quality; and
(i) the written system to recall any batch of product from sale
or supply is followed whenever a recall is necessitated.
SECTION – 6
MATERIALS
Material general:
6.1.1 Quarantine: All incoming materials and finished products shall
be quarantined immediately after receipt or processing, until they
are released for use or distribution.
6.1.2 Appropriate storage: All materials and product shall be stored
under the appropriate conditions established by the manufacturer
and in an orderly manner to permit batch segregation and stock rotation
by a first-in, first-out rule.
Starting materials:
6.2.1 Purchase: The purchase of starting materials is an important
operation that must involve staff who have a particular and thorough
knowledge of the products and suppliers and a pharmacist with some
experience of production may be preferred.
6.2.2 Purchase from producer or established suppliers: Starting
materials shall be purchased directly from the producer or only
from established suppliers.
6.2.3 Checking of Containers: For each consignment, the containers
shall be checked for integrity of package and seal and for correspondence
between the order, the delivery note, and the supplier’s labels,
and, containers shall be cleaned where necessary and labeled, if
required, with the prescribed data.
6.2.4 Damaged container: Damage to containers and any other problem
that might adversely affect the quality of a materials shall be
recorded and reported to the quality control department and investigated.
6.2.5 Delivery from different batches: If a delivery of material
is made up of different batches, each batch shall be considered
as separate for sampling, testing, and release.
6.2.6 Labeling: Starting materials in the storage area shall be
appropriately labeled, and labels shall bear at least the following
information, namely: -
(a) the designated name of the product and the internal code reference
where applicable;
(b) the batch number(s) given by the supplier and on receipt by
the manufacture, if any;
(c) where appropriate, the status of the contents such as on quarantine,
on test, released, rejected, returned, and recalled; and,
(d) where appropriate, and expiry date or a date beyond which retesting
is necessary. When fully computerized storage systems are used appropriate
system shall be developed for the identification of above referred
information.
6.2.7 Identity of contents: There shall be appropriate procedures
or measures to ensure the identity of the contents of each container
of starting material, and bulk containers from which samples have
been drawn shall be identified.
6.2.8 Released materials to be used: Only starting materials released
by the quality control department and with in their shelf-life shall
be used.
6.2.9 Correct dispensing: Starting materials shall be dispensed
only by designated persons, following a written procedure to ensure
that the correct materials are accurately weighed or measured in
to clean and properly labeled containers.
6.2.10 Checking: Each dispensed material and its weight or volume
shall be independently checked and the check recorded.
6.2.11 Labeling: Materials dispensed for each batch of the final
product shall be kept together and conspicuously labeled as such.
6.3 Packaging materials:
6.3.1 Purchase: The purchase, handling and control of primary and
printed packaging materials shall be as for starting materials.
6.3.2 Printed materials: Particular attention shall be paid to printed
packaging materials which shall be stored in secure conditions so
as to exclude the possibility of unauthorized access, cut labels
and other printed materials shall be stored and transported in separate
closed containers so as to avoid mix-ups and packaging materials
shall be issued for use only by designated personnel following an
approved and documented procedure.
6.3.3 Reference numbers: Each delivery or batch of printed or primary
packaging material shall be given a specific reference number or
identification mark.
6.3.4 Obsolete materials: Outdated or obsolete primary packaging
material or printed packaging material shall be destroyed and its
disposal be recorded.
6.3.5 Checking before delivery: All products and packaging materials
to be used shall be checked on delivery to the packaging department
for quantity, identity, and conformity with the packaging instructions.
6.4 Intermediate and bulk products:
6.4.1 Storage: Intermediate and bulk products shall be kept under
appropriate conditions.
6.4.2 Handling: Intermediate and bulk products purchased as such
shall be handled on receipt as though they were starting materials.
6.5 Finished pharmaceutical products:
6.5.1 Quarantine: Finished pharmaceutical products shall be held
in quarantine until their final release, and thereafter they shall
be stored as usable stock under conditions established by the manufacturer.
6.5.2 Release: The evaluation of finished products and the documentation
necessary for release of a product for sale, as per requirement
of these rules, shall be followed.
6.6 Rejected and recovered materials:
6.6.1 Storage and disposal: Rejected materials and products shall
be clearly marked as such and stored separately in restricted areas,
and they shall either be returned to the suppliers or, where appropriate,
reprocessed or destroyed, and then action shall be approved by authorized
personnel and recorded.
6.6.2 Reprocessing: The reprocessing of rejected products shall
be exceptional, it is permitted only if the quality of the final
product is not affected, if the specifications are met, and if it
is done in accordance with a defined and authorized procedure after
evaluation of the risks involved and record shall be kept of the
reprocessing and a reprocessed batch shall be given a new batch
number.
6.6.3 Batch recovery: The introduction of all or part of earlier
batches, conforming to the required quality, in to a batch of the
same product at a defined stage of manufacture shall be authorized
beforehand, this recovery shall be carried out in accordance with
a defined procedure after evaluation of the risks involved, including
any possible effect on shelf-life and the recovery shall be recorded.
6.6.4 Additional testing of reprocessed materials: The need for
additional testing of any finished product that has been reprocessed
, or into which a recovered product has been incorporated, shall
be considered by the quality control department.
6.7 Recalled and returned products:
6.7.1 Recalled products: Recalled products shall be identified,
clearly marked as such and stored separately in a secure area until
a decision is taken on their fate.
6.7.2 Returned goods; Products returned from the m |
